Hem › Multipelt myelom › Ohio › Cincinnati
Kliniska studier för Multipelt myelom i Cincinnati, OH
17 studier för Multipelt myelom söker deltagare vid platser i och runt Cincinnati (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekryterarFas 3
- Research Site, Cincinnati
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 3
- The Christ Hospital, Cincinnati
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekryterarFas 3
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekryterarFas 2
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · 15 mi bort
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekryterarFas 3
- University of Cincinnati Medical Center, Cincinnati
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 2
- Oncology Hematology Care, Cincinnati
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RekryterarFas 3
- TriHealth Cancer and Blood Institute, Cincinnati
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RekryterarFas 3
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- och 4 fler
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RekryterarFas 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- och 1 fler
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekryterarFas 3
- Research Site, Cincinnati
- Research Site, Montgomery · 11 mi bort
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekryterarFas 1/2
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 1
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RekryterarFas 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- och 2 fler
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekryterarFas 3
- University of Cincinnati, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekryterarFas 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
RekryterarFas 2
- Oncology Hematology Care, Cincinnati
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekryterarFas 1
- Oncology Hematology Care, Inc, Cincinnati
Multipelt myelom-studier i andra städer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
Andra studier i Cincinnati
- Icke-småcellig lungcancer35 studier
- Cancer (alla typer)27 studier
- Bröstcancer25 studier
- Hjärtsvikt24 studier
- Kolorektal cancer21 studier
- Akut myeloid leukemi20 studier
- Metastaserande cancer20 studier
- Äggstockscancer19 studier
- Lungcancer19 studier
- Övervikt19 studier
- Prostatacancer18 studier
- Melanom17 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.